NO2539366T3 - - Google Patents
Info
- Publication number
- NO2539366T3 NO2539366T3 NO11713058A NO11713058A NO2539366T3 NO 2539366 T3 NO2539366 T3 NO 2539366T3 NO 11713058 A NO11713058 A NO 11713058A NO 11713058 A NO11713058 A NO 11713058A NO 2539366 T3 NO2539366 T3 NO 2539366T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30863810P | 2010-02-26 | 2010-02-26 | |
| US40626010P | 2010-10-25 | 2010-10-25 | |
| PCT/IB2011/050826 WO2011104696A1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2539366T3 true NO2539366T3 (da) | 2018-04-07 |
Family
ID=44227520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO11713058A NO2539366T3 (da) | 2010-02-26 | 2011-02-25 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8632776B2 (da) |
| EP (1) | EP2539366B1 (da) |
| JP (1) | JP5894939B2 (da) |
| CN (3) | CN106397588B (da) |
| AU (1) | AU2011219414B2 (da) |
| CA (1) | CA2789963C (da) |
| CY (1) | CY1120014T1 (da) |
| DK (1) | DK2539366T3 (da) |
| ES (1) | ES2661925T3 (da) |
| HR (1) | HRP20180230T8 (da) |
| HU (1) | HUE038313T2 (da) |
| LT (1) | LT2539366T (da) |
| NO (1) | NO2539366T3 (da) |
| PL (1) | PL2539366T3 (da) |
| PT (1) | PT2539366T (da) |
| RS (1) | RS57029B1 (da) |
| RU (1) | RU2555526C2 (da) |
| SI (1) | SI2539366T1 (da) |
| SM (1) | SMT201800044T1 (da) |
| WO (1) | WO2011104696A1 (da) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190092T1 (hr) | 2008-04-29 | 2019-03-22 | Bioarctic Ab | Antitijela i cjepiva za uporabu u terapijskim i dijagonstičkim postupcima za poremećaje vezane uz alfa-sinuklein |
| DK2539366T3 (da) | 2010-02-26 | 2018-02-05 | Bioarctic Neuroscience Ab | Protofibril-bindende antistoffer og deres anvendelse i terapeutiske og diagnostiske fremgangsmåder for parkinsons sygdom, demens med lewy body og andre alpha-synukleinopatier |
| US11249092B2 (en) | 2017-05-16 | 2022-02-15 | Amprion, Inc. | Detection of misfolded tau protein |
| EP3604339B1 (en) | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| LT2804878T (lt) * | 2012-01-20 | 2018-12-10 | Genzyme Corporation | Anti-cxcr3 antikūnai |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| CN111499743B (zh) | 2013-11-21 | 2024-01-12 | 豪夫迈·罗氏有限公司 | 抗-α-突触核蛋白抗体及使用方法 |
| UA121550C2 (uk) * | 2014-07-10 | 2020-06-25 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | АНТИТІЛО, ЯКЕ ЗВ'ЯЗУЄ A<font face="Symbol">b</font>-ПРОТОФІБРИЛИ |
| WO2016040905A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded alpha synuclein protein |
| EP3207057A2 (en) | 2014-10-16 | 2017-08-23 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
| CA2977646A1 (en) | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| EP3325506A1 (en) | 2015-07-21 | 2018-05-30 | BioArctic AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| KR20180094876A (ko) | 2015-11-09 | 2018-08-24 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 에피토프 및 이에 대한 항체 |
| HK1259325A1 (zh) | 2015-11-09 | 2019-11-29 | 英属哥伦比亚大学 | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 |
| KR102786245B1 (ko) | 2015-11-09 | 2025-03-26 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 |
| KR102355950B1 (ko) | 2016-03-04 | 2022-01-26 | 제이엔 바이오사이언시즈 엘엘씨 | Tigit에 대한 항체 |
| BR112018074978A2 (pt) | 2016-06-02 | 2019-03-12 | Medimmune Limited | anticorpos para alfa-sinucleína e usos dos mesmos |
| SG11201810801QA (en) | 2016-07-14 | 2019-01-30 | Bioarctic Ab | Brain delivery protein |
| CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| MX2019005594A (es) | 2016-11-15 | 2019-07-04 | H Lundbeck As | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. |
| MA47019A (fr) | 2016-12-16 | 2021-04-21 | H Lundbeck As | Agents, utilisations et procédés |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| AU2018206279B2 (en) * | 2017-01-06 | 2020-09-03 | Abl Bio Inc. | Anti-alpha-syn antibody and use thereof |
| US11142570B2 (en) * | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| EP3612566A4 (en) * | 2017-04-21 | 2021-03-03 | Implicit Bioscience Limited | CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| US11220538B2 (en) | 2017-05-01 | 2022-01-11 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| CN111225923B (zh) * | 2017-08-02 | 2024-09-24 | 思瑞麦科生物科技公司 | 结合活性α突触核蛋白的抗体 |
| WO2019040617A1 (en) | 2017-08-23 | 2019-02-28 | The Trustees Of The University Of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME |
| RU2657763C1 (ru) * | 2017-09-12 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики болезни паркинсона |
| JP7173618B2 (ja) * | 2017-11-17 | 2022-11-16 | エービーエル バイオ インコーポレイテッド | アルファ－シヌクレインに対する抗体およびその用途 |
| AU2018385230B2 (en) | 2017-12-14 | 2022-10-13 | Abl Bio Inc. | Bispecific antibody to a-syn/IGF1R and use thereof |
| GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| PL3728567T3 (pl) | 2017-12-19 | 2023-11-13 | Chase Therapeutics Corporation | Metoda oceny synukleinopatii |
| ES2898929T3 (es) * | 2017-12-21 | 2022-03-09 | H Lundbeck As | Diagnóstico y tratamiento de alfa-sinucleinopatías |
| CN109957547A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957546A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019195432A1 (en) * | 2018-04-04 | 2019-10-10 | University Of Florida Research Foundation, Inc. | Materials and methods for the treatment of lewy body disorders |
| TW202003576A (zh) * | 2018-05-10 | 2020-01-16 | 美商艾博視訊有限公司 | 活化cd40之單株抗體及其用途 |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| CA3107370A1 (en) | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| JP2022505152A (ja) * | 2018-10-19 | 2022-01-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 抗シヌクレイン抗体 |
| CN113195538B (zh) * | 2018-12-12 | 2023-03-14 | 上海药明生物技术有限公司 | 抗tim-3抗体及其用途 |
| RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| WO2020192754A1 (en) * | 2019-03-28 | 2020-10-01 | The Chinese University Of Hong Kong | Sumo peptides for treating neurodegenerative diseases |
| CN114341343B (zh) * | 2019-04-30 | 2024-11-15 | 才思治疗公司 | α-突触核蛋白测定 |
| US20220291240A1 (en) * | 2019-08-27 | 2022-09-15 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| CA3163308A1 (en) | 2019-12-31 | 2021-07-08 | Thomas N. Chase | Kinases as biomarkers for neurodegenerative conditions |
| CN111171152B (zh) * | 2020-01-15 | 2023-04-18 | 吉林医药学院 | Pcsk9抗体及其制备方法和应用 |
| NL2025332B1 (en) * | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| RS66984B1 (sr) * | 2020-06-26 | 2025-07-31 | Bioarctic Ab | Antitela koja vezuju alfa-sinuklein protofibril |
| US20230365665A1 (en) | 2020-09-17 | 2023-11-16 | Qatar Foundation For Education, Science And Community Development | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES |
| CA3225302A1 (en) | 2021-07-09 | 2023-01-12 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| KR20240053620A (ko) | 2021-08-30 | 2024-04-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법 |
| EP4473009A1 (en) | 2022-02-02 | 2024-12-11 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| CN116589567B (zh) * | 2022-11-30 | 2024-03-19 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2329523A1 (en) | 1998-07-03 | 2000-01-13 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| US20060018918A1 (en) | 2000-12-27 | 2006-01-26 | Board Of Regents, The University Of Texas System | Production of stabilized conformational isomers of disease associated proteins |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| NZ547588A (en) * | 2003-11-07 | 2009-05-31 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| CA2641219A1 (en) | 2006-01-31 | 2007-08-09 | Elan Pharmaceuticals, Inc. | Alpha-synuclein kinase |
| PL2004688T5 (pl) | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101161245B (zh) * | 2007-11-29 | 2011-11-09 | 首都医科大学宣武医院 | 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途 |
| HRP20190092T1 (hr) | 2008-04-29 | 2019-03-22 | Bioarctic Ab | Antitijela i cjepiva za uporabu u terapijskim i dijagonstičkim postupcima za poremećaje vezane uz alfa-sinuklein |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| DK2539366T3 (da) | 2010-02-26 | 2018-02-05 | Bioarctic Neuroscience Ab | Protofibril-bindende antistoffer og deres anvendelse i terapeutiske og diagnostiske fremgangsmåder for parkinsons sygdom, demens med lewy body og andre alpha-synukleinopatier |
-
2011
- 2011-02-25 DK DK11713058.3T patent/DK2539366T3/da active
- 2011-02-25 AU AU2011219414A patent/AU2011219414B2/en active Active
- 2011-02-25 JP JP2012554464A patent/JP5894939B2/ja active Active
- 2011-02-25 CN CN201610801424.7A patent/CN106397588B/zh active Active
- 2011-02-25 CN CN201910950804.0A patent/CN110655573B/zh active Active
- 2011-02-25 EP EP11713058.3A patent/EP2539366B1/en active Active
- 2011-02-25 RS RS20180129A patent/RS57029B1/sr unknown
- 2011-02-25 CN CN201180011363.XA patent/CN102869680B/zh active Active
- 2011-02-25 PL PL11713058T patent/PL2539366T3/pl unknown
- 2011-02-25 US US13/578,710 patent/US8632776B2/en active Active
- 2011-02-25 RU RU2012140954/10A patent/RU2555526C2/ru active
- 2011-02-25 NO NO11713058A patent/NO2539366T3/no unknown
- 2011-02-25 LT LTEP11713058.3T patent/LT2539366T/lt unknown
- 2011-02-25 CA CA2789963A patent/CA2789963C/en active Active
- 2011-02-25 WO PCT/IB2011/050826 patent/WO2011104696A1/en not_active Ceased
- 2011-02-25 HU HUE11713058A patent/HUE038313T2/hu unknown
- 2011-02-25 SM SM20180044T patent/SMT201800044T1/it unknown
- 2011-02-25 PT PT117130583T patent/PT2539366T/pt unknown
- 2011-02-25 SI SI201131419T patent/SI2539366T1/en unknown
- 2011-02-25 ES ES11713058.3T patent/ES2661925T3/es active Active
- 2011-02-25 HR HRP20180230TT patent/HRP20180230T8/hr unknown
-
2013
- 2013-08-01 US US13/957,239 patent/US8859501B2/en active Active
-
2014
- 2014-08-28 US US14/472,036 patent/US8968734B2/en active Active
-
2015
- 2015-02-02 US US14/611,690 patent/US9084832B2/en active Active
-
2018
- 2018-02-05 CY CY20181100140T patent/CY1120014T1/el unknown